We are committed to curing patients by developing a pipeline of revolutionary therapeutics that unlock the full potential of well-studied pathways. We are focusing on diseases that involve the delicate control mechanisms of the immune system, including cancer, autoimmune and inflammatory diseases.
AULOS – AU-007

Selective effector cells agonist for IO

This is illustrated by AU-007, the first-ever computationally designed antibody to enter human clinical trials. AU-007 was designed by Biolojic to precisely bind to pre-defined epitope on interleukin-2 (IL-2) to redirect IL-2 toward cells that express dimeric receptors (T effs, NKs, NKTs), and away from cells that express the trimeric receptor (T regs, vascular endothelium). Thus, AU-007 unlocks the full potential of IL-2 to fight cancer: it starves the cells that protect the tumor and nourishes that cells that kill the tumor.

Unlocking the Power of IL-2

Interleukin-2 is often described as a “double-edged sword” because of its ability both to suppress and activate the immune system. For cancer patients, increased levels of IL-2 correlate with improved survival.


Dual Specific Antibody Targeting Two Cytokines

Our anti-IL-13 / TSLP multibody is designed to treat inflammatory diseases. This is the first multibody ever in development.

Our anti-IL-13 / TSLP multibody is designed to treat inflammatory diseases. This is the first multibody ever in development.

Current drugs that attack this pathway are blockbusters, validating the great need, but each of them works only for about half of the patients. Why?

The pathway of these diseases involves changing levels of the thymic stromal lymphopoietin (TSLP) and of Interleukin 13 (IL-13) over time. Existing drugs focus on only one of these two drivers of inflammation, and do not respond to pathway dynamics.

BD9 can block both TSLP and IL-13. When TSLP is upregulated BD9 binds it with both arms and ultra-high affinity. When IL-13 is upregulated, BD9 can bind it with both arm and very high affinity. Thus, BD9 can help more patients and improve outcomes for existing respondents.

This is an example of how Biolojic’s technology can solve one of the greatest challenges in drug development: BD9 will be given to all patients in the same way and yet it will have personalized activity – it will adjust its activity to what is needed for a specific patient, at a specific time in a specific tissue.


Selective Tregs agonist antibody for autoimmune diseases

BD3 redirects the cytokine interleukin-2 (IL-2) away from effector T cells, which are the cells that exacerbate autoimmune responses, toward regulatory T cells, which are the cells that inhibit autoimmune responses.

Thus, by controlling natural IL-2, BD3 uses the cytokine made by effector cells, against the effector cells themselves. It starves the cells that attack the tissue and expands the cells that protect it. As the only antibody that is developed for this pathway, BD3 is expected to have better efficacy, safety and longer half-life than any other IL-2 based treatment for autoimmune diseases.

Super Engagers for IO and Hematological Malignancies

Super-engagers are two multibodies fused to each other in a bispecific format:

The first arm is a multibody that binds to two immune targets — either a marker on NK cells or a marker on Teffs cells. This allows super-engagers to bring to the tumor two different types of cytotoxic cells to increase efficacy and potentially reduce toxicity

The second arm is a multibody that binds to two different tumor antigens. Thus increases the therapeutic index by increasing the density of engager on tumor cells, accounting for the heterogeneity of the expression of tumor antigens on different cancer cells.

Biolojic Design has two early super-engager programs, one in oncology and one in hematology.
What’s New